The mutation type was the most important determinant of expression levels.[24] Although previous studies have reported mutations in the TP53,[6–9] PI3K,[6] and MAPK [10] pathways in angiosarcoma, these studies were genomic screening studies that did not examine protein levels. The gene discussed is TP53; the disease is angiosarcoma.